circle

INVESTORS & MEDIA

INVESTOR OVERVIEW

  • Webcast
    X JMP Securities Life Sciences Conference
    Jun 19, 2019 9:00 AM EDT

    JMP Securities Life Sciences Conference
    Jun 19, 2019 9:00 AM EDT
  • Webcast
    X Cytokinetics, Inc. Annual Shareholder Meeting
    May 15, 2019 10:30 AM PDT

    Cytokinetics, Inc. Annual Shareholder Meeting
    May 15, 2019 10:30 AM PDT

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and best-in-class muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. Cytokinetics is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. More >>

ANNUAL REPORT

CORPORATE PRESENTATION

CYTOKINETICS FACT SHEETS

fact1

Company

09/21/18
( FY )
ALS

ALS

03/11/18
( FY )
SMA

SMA

07/13/18
( FY )

NEWS

Date Title and Summary
Toggle Summary Cytokinetics Announces Completion of Enrollment in GALACTIC-HF, Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients With Heart Failure
Clinical Trial Enrolled Over 8,200 Patients With Reduced Ejection Fraction in 35 Countries SOUTH SAN FRANCISCO, Calif. , July 15, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the completion of patient enrollment in GALACTIC-HF ( G lobal A pproach to L owering A
Toggle Summary Cytokinetics Announces Preclinical Data For Reldesemtiv Presented at the 2019 Annual Cure SMA Conference
Two Studies Show Addition of Reldesemtiv to SMN-Directed Treatment Increases Muscle Force in Mouse Model of Spinal Muscular Atrophy SOUTH SAN FRANCISCO, Calif. , June 28, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that data from two preclinical studies of
Toggle Summary Cytokinetics Announces Preclinical Data for Reldesemtiv to be Presented at the 2019 Annual Cure SMA Conference
SOUTH SAN FRANCISCO, Calif. , June 24, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that two preclinical poster presentations on the addition of reldesemtiv to treatment with SMN upregulators ( nusinersen and SMN-C1, an analogue to risdiplam ) will be presented
Toggle Summary Cytokinetics to Present at the JMP Securities Life Sciences Conference
SOUTH SAN FRANCISCO, Calif. , June 12, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK ) today announced that Robert I. Blum , President and Chief Executive Officer, is scheduled to present a corporate update at the JMP Securities Life Sciences Conference on Wednesday, June 19,

EVENTS

There are currently no events to display.